Interferon gamma News and Research

RSS

Children exhibit distinct immune system responses against COVID-19

Children and adults exhibit distinct immune system responses to infection by the virus that causes COVID-19, a finding that helps explain why COVID-19 outcomes tend to be much worse in adults, researchers from Yale and Albert Einstein College of Medicine report Sept. 18 in the journal Science Translational Medicine.

23 Sep 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

India's whole-virion inactivated SARS-CoV-2 vaccine shows promise

Researchers in India have conducted a preclinical study demonstrating the safety and efficacy of a new candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

13 Sep 2020

Study sheds light on how interferon-gamma drives response to immunotherapy in melanoma

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -; immune checkpoint blockade.

10 Sep 2020

'Molecular brake' on the immune system could be potential treatment target for severe COVID-19

Older people and people with underlying medical conditions are at particular risk of severe COVID-19. A group of researchers from Charité - Universitätsmedizin Berlin have discovered one possible reason for this vulnerability.

8 Sep 2020

Research compares T cell responses to SARS-CoV-2 and influenza

As the COVID-19 pandemic continues to grow, scientists are focusing on understanding how the host immune system responds to the virus in order to better shape public health responses and develop effective vaccines. A new study published on the preprint server medRxiv in September 2020 reports the T cell memory response to the SARS-CoV-2 spike protein, recombinant nucleocapsid protein, and other pooled peptides derived from convalescent patients.

3 Sep 2020

Study identifies subtypes and developmental process of novel immune T cells

There are memory cells that remember previously encountered pathogens and help to react quickly and strongly when exposed to them again.

2 Sep 2020

Genes on the X chromosome may be key to melanoma survival advantage in females

Centenary Institute scientists have discovered that genes on the X chromosome may be key to the improved survival rates of females with melanoma–as compared to their male counterparts.

13 Aug 2020

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020

Study reveals manifold applications of cytokine transcriptional response modules in COVID-19

In a recent bioRxiv* study, UK researchers used interleukin modules to investigate the pathology of coronavirus disease (COVID-19).

27 Jul 2020

Study shows interferons do not induce the expression of SARS-CoV-2 cell entry receptor

In a new bioRxiv study, authors identified a isoform of ACE2 (designated as deltaACE2 or dACE2) receptor, shown to be induced in various human cell types.

23 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

Dysfunctional T cells present at high levels in severe COVID-19

Now, a new study by researchers at Saarland University, Germany, and published on the preprint server medRxiv in July 2020 shows that there are higher levels of anti-SARS-CoV-2 T cells, which show significant alterations in the phenotype and function.

12 Jul 2020

Dysregulated inflammation in severe COVID-19

The continuing COVID-19 pandemic has so far caused 9.58 million cases and more than 488,000 deaths within just six months. The spectrum of disease is broad, from completely asymptomatic cases to critical illness ending in death. Now, a new paper by researchers from Yale University and published on the preprint server medRxiv* in June 2020 identifies an imbalance in immunological response that is linked to poor outcomes and early biomarkers that may help predict the course of the disease.

25 Jun 2020

Research team profiles the body's immune response to COVID-19

A team from Lawson Health Research Institute and Western University are the first in the world to profile the body's immune response to COVID-19.

25 Jun 2020

Exposure to SARS-CoV-2 can induce virus-specific T cell responses without seroconversion

A new study by researchers at Strasbourg University Hospital and published on the preprint server medRxiv* in June 2020 shows that COVID-19 antibody responses may sometimes be lacking following exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could lead to a significant underestimation of the number of infections and the number of individuals who have achieved immunity.

24 Jun 2020

Progression and severity of COVID-19 highly dependant on cytokine changes

A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).

11 Jun 2020

Immune modulation can cure severe and often fatal fungal infection in children

In the June 11 issue of the New England Journal of Medicine, a team of UCLA physicians and scientists describes the first case of immune modulation being used to cure a severe and often fatal fungal infection.

11 Jun 2020

Specific immune signature identified in COVID-19 patients

Researchers at King’s College London and collaborators have identified an “immune signature” that could help researchers better understand coronavirus disease 2019 (COVID-19) and serve as a valuable resource for predicting patient prognosis and informing clinical risk-based stratification.

10 Jun 2020